Clinical Lymphoma, Myeloma and Leukemia

Published by: Elsevier Inc.  

People

  1. Mauro
    Mauro
  2. Giralt
    Giralt
  3. Landau
    Landau
  4. Hassoun
    Hassoun
  5. Lesokhin
    Lesokhin
  6. Usmani
    Usmani
  7. Hultcrantz
    Hultcrantz
  8. Mailankody
    Mailankody
  9. Horwitz
    Horwitz
  10. Shah
    Shah

Groups

  1. Department of Medicine (238)
  2. Hematologic Malignancies, Division of (236)
  3. Center for Hematologic Malignancies (227)
  4. Adult Leukemia (104)
  5. Lymphoma (56)
  6. Survivorship Research (51)
  7. Myeloma (50)
  8. Hematologic Malignancies Research (49)
  9. Population Sciences Research Program (48)
  10. Bone Marrow Transplant (43)
Search Within
Formats
  1. Meeting Abstract (203)
  2. Journal Article (64)
  3. Review (3)
  4. Conference Paper (1)
  5. Guidelines (1)
  6. Research Letter (1)
Groups
  1. Department of Medicine (238)
  2. Hematologic Malignancies, Division of (236)
  3. Center for Hematologic Malignancies (227)
  4. Adult Leukemia (104)
  5. Lymphoma (56)
  6. Survivorship Research (51)

More Groups

People
  1. Michael Mauro (38)
  2. Heather Landau (29)
  3. Sergio Giralt (29)
  4. Hani Hassoun (26)
  5. Alexander Lesokhin (22)
  6. Saad Usmani (22)

More People

Years
  1. 2023 (3)
  2. 2022 (64)
  3. 2021 (40)
  4. 2020 (29)
  5. 2019 (38)
  6. 2018 (17)

More Years

Publishers
  1. Elsevier Inc. (273)

Results (273)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comparative efficacy of teclistamab versus physician's choice of therapy in the long-term follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS clinical trials in patients with triple-class exposed relapsed or refractory multiple myeloma
    Journal Article

    Mateos, M. V.; Chari, A.; Usmani, S. Z.; Goldschmidt, H.; Weisel, K.; Qi, K.; Londhe, A.; Nair, S.; Lin, X.; Pei, L.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Outcomes for patients with chronic lymphocytic leukemia (CLL) previously treated with both a covalent BTK and BCL2 inhibitor in the United States: A real-world database study
    Journal Article

    Mato, A. R.; Hess, L. M.; Chen, Y.; Abada, P. B.; Konig, H.; Pagel, J. M.; Walgren, R. A.
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Standardizing clinical workflow for assessing minimal residual disease by flow cytometry in multiple myeloma
    Journal Article

    Foureau, D. M.; Paul, B. A.; Guo, F.; Lipford, E. H.; Fesenkova, K.; Tjaden, E.; Drummond, K.; Bhutani, M.; Atrash, S.; Ndiaye, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: Initial experience in two clinical trials
    Meeting Abstract

    Qualls, D.; Monette, S.; Sethi, S.; Dogan, A.; Roshal, M.; Senechal, B.; Wang, X.; Riviere, I.; Sadelain, M.; Brentjens, R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • CARTITUDE-1: Two-year post last patient in (LPI) results from the phase 1b/2 study of ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T (CAR-T) cell therapy, in patients with relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Usmani, S. Z.; Martin, T.; Berdeja, J. G.; Jakubowiak, A.; Agha, M.; Cohen, A. D.; Deol, A.; Htut, M.; Lesokhin, A.; Munshi, N. C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Interventions and outcomes of multiple myeloma patients progressing after BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy
    Meeting Abstract

    Van Oekelen, O.; Nath, K.; Mouhieddine, T. H.; Farzana, T.; Aleman, A.; Melnekoff, D. T.; Ghodke-Puranik, Y.; Jagannath, S.; Shah, U. A.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma (RRMM): DREAMM-14
    Meeting Abstract

    Hultcrantz, M.; Kleinman, D.; Ghataorhe, P.; McKeown, A.; He, W.; Ling, T.; Jewell, R. C.; Byrne, J.; Eliason, L.; Scott, E.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed/refractory (R/R) follicular lymphoma (FL) who have received ≥2 prior lines of therapy: Pivotal results from a phase I/II study
    Meeting Abstract

    Budde, E. L.; Sehn, L. H.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Subcutaneous epcoritamab with rituximab + lenalidomide (R(2)) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial
    Meeting Abstract

    Falchi, L.; Leppä, S.; Wahlin, B. E.; Nijland, M.; Christensen, J. H.; De Vos, S.; Holte, H.; Linton, K. M.; Abbas, A.; Wang, L. W.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: Updated results from the phase 1/2 BRUIN study
    Meeting Abstract

    Cohen, J. B.; Shah, N. N.; Alencar, A. J.; Gerson, J. N.; Patel, M. R.; Fakhri, B.; Jurczak, W.; Tan, X. N.; Lewis, K. L.; Fenske, T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save

    • Clinical Lymphoma, Myeloma and Leukemia – authorized name for:

    Name ISSN / ISBN Publisher
    Clinical Lymphoma Myeloma & Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma Myeloma & Leukemia 2152-2650 Cancer Media Group
    Clinical Lymphoma Myeloma & Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma Myeloma & Leukemia 2152-2650 Cig Media Group, Lp
    Clinical Lymphoma, Myeloma & Leukemia 21522669 Unknown
    Clinical Lymphoma, Myeloma & Leukemia 2152-2650 Unknown
    Clinical Lymphoma, Myeloma & Leukemia 1368-8375 Unknown
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522669 Unknown
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522650 Unknown
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 152-2650 2021
    Clinical Lymphoma, Myeloma and Leukemia 21522650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522650 Elsevier Ltd
    Clinical Lymphoma, Myeloma and Leukemia 21522650 2022
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522669 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522650 The Authors
    Clinical Lymphoma, Myeloma and Leukemia 21522650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522650 2021
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.